NEW YORK – PCR assay maker Molecular Designs said Wednesday that it has acquired Lamda Biotech, a provider of research products for molecular biology, functional genomics, proteomics, and gene therapy.
Financial and other details of the deal were not disclosed.
"For more than 20 years, Lamda Biotech has been highly regarded for its offering of cutting-edge PCR products, RT-PCR reagents, RT-qPCR kits, Direct-PCR genotyping kits, DNA ladders, SafeStain, and other protein and cell biology products," Molecular Designs said in a statement, adding that the deal will enhance its product portfolio and help grow its reach into the academic research and pharma market segments.
Molecular Designs is based in Birmingham, Alabama, while Lamda Biotech is based in St. Louis.